GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
K

Kingworld Medicines Group 1110.HK · HKD

Health Care · HKEX · 🇭🇰 Hong Kong

Compare

0.40

+1.28%

Close of 9 Nov 2026, in HKD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Kingworld Medicines Group

Its shares trade on HKEX under the ticker 1110.HK. It has been listed since 25 November 2010. In the fiscal year to 31 December 2025, it reported revenue of CN¥917.3m and net income of CN¥11.3m. At that date it held total assets of CN¥1.44bn and shareholders' equity of CN¥618.0m.

Kingworld Medicines Group Ltd. is an investment company, which engages in the distribution of imported branded pharmaceutical and healthcare products. The company is headquartered in Shenzhen, Guangdong. The company went IPO on 2010-11-25. The Company’s products include cough and phlegm relieving, gastrointestinal, vitamin, orthopedics, cardiovascular, influenza and others. The firm operates through two business segments. The Distribution Sales of Pharmaceutical and Healthcare Products segment is engaged in the distribution and sales of branded imported pharmaceutical and healthcare products primarily in Hong Kong and the People’s Republic of China (PRC). The Manufacturing and Sales of Electrotherapeutic and Physiotherapeutic Devices and General Medical Examination Devices segment is engaged in the manufacture and sales of electrotherapeutic and physiotherapeutic devices, as well as general medical examination devices in the PRC.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Health Care Providers & Services
Listed since
25 Nov 2010
Employees
1,019

Leadership

Pay as last reported

  • Mr. Li Sheng ZhaoExecutive Chairman of the Board, Chief Executive Officer, since 2008CN¥1.4m
  • Mr. Hon Wan ChanFinancial Controller, Company Secretary, Authorised Representative
  • Ms. Lok San ChanExecutive Director, since 2008CN¥1.2m
  • Mr. Xuhua ZhouGeneral Manager of SZ Kingworld, Executive Director, since 2009CN¥496,000
  • Mr. Yun CengSales Controller - Commerce of SZ Kingworld, since 2015
  • Mr. Yong ChenManager - Finance Department of SZ Kingworld
  • Mr. Yueyue ChenController of SZ Kingworld, East China
  • Ms. Danna FangFinancial Manager of SZ Kingworld
  • Mr. Jia Zhi FangManager - Investment Center
  • Mr. Ruozhong HuangCorporate Finance Controller of SZ Kingworld
  • Mr. Zhihui HuangManager - Audit and Supervision Center
  • Mr. Jinwu LiuDeputy Controller - Pharmaceutical Department of SZ Kingworld

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Kingworld Medicines Group Ltd employs 1,019 full-time employees in Shenzhen, China.
  • The company distributes branded pharmaceutical products in Hong Kong and the People's Republic of China.
  • Kingworld Medicines Group Ltd manufactures electrotherapeutic devices in the People's Republic of China.

Weaknesses

  • Kingworld Medicines Group Ltd has no manufacturing presence outside the People's Republic of China.
  • The company's distribution segment focuses solely on Hong Kong and the People's Republic of China.
  • Kingworld Medicines Group Ltd's product range includes only cough and phlegm relieving and cardiovascular products.

Opportunities

  • Kingworld Medicines Group Ltd could expand its manufacturing segment into new markets beyond the People's Republic of China.
  • The company may increase its product range to include more healthcare segments.
  • Kingworld Medicines Group Ltd might leverage its distribution network for new product lines in Hong Kong.

Threats

  • Kingworld Medicines Group Ltd faces competition from other pharmaceutical distributors in the People's Republic of China.
  • The company's manufacturing segment could be affected by regulatory changes in the People's Republic of China.
  • Kingworld Medicines Group Ltd's distribution segment is limited to Hong Kong and the People's Republic of China.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.